688247 宣泰医药
已收盘 08-10 15:00:00
资讯
新帖
简况
宣泰医药新提交“宣泰小红片”、“O'red”等3件商标注册申请
证券之星 · 08-05
宣泰医药新提交“宣泰小红片”、“O'red”等3件商标注册申请
股市必读：宣泰医药新发布《自愿披露关于参与全国药品集中采购拟中选的公告》
证券之星 · 08-05
股市必读：宣泰医药新发布《自愿披露关于参与全国药品集中采购拟中选的公告》
宣泰医药(688247.SH)：注射用硫酸艾沙康唑等拟中选全国药品集中采购
智通财经 · 08-03
宣泰医药(688247.SH)：注射用硫酸艾沙康唑等拟中选全国药品集中采购
每周股票复盘：宣泰医药（688247）复杂注射剂产线试生产成功
证券之星 · 07-26
每周股票复盘：宣泰医药（688247）复杂注射剂产线试生产成功
宣泰医药：泊沙康唑肠溶片通过欧盟DCP核准
格隆汇 · 07-24
宣泰医药：泊沙康唑肠溶片通过欧盟DCP核准
每周股票复盘：宣泰医药（688247）多索茶碱片通过一致性评价
证券之星 · 07-19
每周股票复盘：宣泰医药（688247）多索茶碱片通过一致性评价
宣泰医药（688247）披露多索茶碱片通过仿制药一致性评价并新增规格公告，7月13日股价上涨2.13%
证券之星 · 07-13
宣泰医药（688247）披露多索茶碱片通过仿制药一致性评价并新增规格公告，7月13日股价上涨2.13%
每周股票复盘：宣泰医药（688247）股价涨幅偏离值累计超30%
证券之星 · 07-05
每周股票复盘：宣泰医药（688247）股价涨幅偏离值累计超30%
宣泰医药（688247）披露股票交易异常波动公告，7月2日股价上涨5.54%
证券之星 · 07-02
宣泰医药（688247）披露股票交易异常波动公告，7月2日股价上涨5.54%
异动快报：宣泰医药（688247）7月1日10点44分触及涨停板
证券之星 · 07-01
异动快报：宣泰医药（688247）7月1日10点44分触及涨停板
每周股票复盘：XD宣泰医（688247）宣泰医药实施2025年度分红
证券之星 · 06-28
每周股票复盘：XD宣泰医（688247）宣泰医药实施2025年度分红
宣泰医药（688247）披露2025年年度权益分派实施公告，6月22日股价下跌1.06%
证券之星 · 06-22
宣泰医药（688247）披露2025年年度权益分派实施公告，6月22日股价下跌1.06%
每周股票复盘：宣泰医药（688247）股东减持279.24万股致股价跌15.66%
证券之星 · 06-14
每周股票复盘：宣泰医药（688247）股东减持279.24万股致股价跌15.66%
6月10日宣泰医药发布公告，股东减持279.24万股
证券之星 · 06-10
6月10日宣泰医药发布公告，股东减持279.24万股
宣泰医药：公司于2026年5月11日参加了在上海证券交易所上证路演中心举办的“十五五·科创惠民——科创板企业成果转化与民生赋能之2025年度制药行业集体业绩说明会”
证券之星 · 06-05
宣泰医药：公司于2026年5月11日参加了在上海证券交易所上证路演中心举办的“十五五·科创惠民——科创板企业成果转化与民生赋能之2025年度制药行业集体业绩说明会”
每周股票复盘：宣泰医药（688247）盐酸安非他酮获哥伦比亚批准
证券之星 · 05-31
每周股票复盘：宣泰医药（688247）盐酸安非他酮获哥伦比亚批准
宣泰医药（688247）披露2025年年度股东会决议公告，5月28日股价上涨1.29%
证券之星 · 05-28
宣泰医药（688247）披露2025年年度股东会决议公告，5月28日股价上涨1.29%
宣泰医药(688247.SH)：盐酸安非他酮缓释片获得哥伦比亚INVIMA批准文号
智通财经 · 05-25
宣泰医药(688247.SH)：盐酸安非他酮缓释片获得哥伦比亚INVIMA批准文号
每周股票复盘：宣泰医药（688247）2025年净利降62.82%
证券之星 · 05-24
每周股票复盘：宣泰医药（688247）2025年净利降62.82%
宣泰医药（688247）披露2025年年度股东会会议资料，5月22日股价下跌0.45%
证券之星 · 05-22
宣泰医药（688247）披露2025年年度股东会会议资料，5月22日股价下跌0.45%
加载更多
公司概况
公司名称：
上海宣泰医药科技股份有限公司
所属行业：
医药制造业
上市日期：
2022-08-25
主营业务：
上海宣泰医药科技股份有限公司的主营业务是高端仿制药研发与产业化及创新药CRO/CMO一体化服务。公司的主要产品是美沙拉秦肠溶片、泊沙康唑肠溶片、熊去氧胆酸胶囊、盐酸安非他酮缓释片、碳酸司维拉姆片、西格列汀二甲双胍缓释片、达格列净二甲双胍缓释片。公司荣膺“2025中国医药CDMO企业20强”。
发行价格：
9.37
{"stockData":{"symbol":"688247","market":"SH","secType":"STK","nameCN":"宣泰医药","latestPrice":9.32,"timestamp":1786345200000,"preClose":9.29,"halted":0,"volume":10111214,"delay":0,"changeRate":0.0032,"floatShares":453000000,"shares":453000000,"eps":0.0961,"marketStatus":"已收盘","change":0.03,"latestTime":"08-10 15:00:00","open":9.14,"high":9.55,"low":9.14,"amount":94602300,"amplitude":0.0441,"askPrice":9.33,"askSize":470,"bidPrice":9.32,"bidSize":262,"shortable":0,"etf":0,"ttmEps":0.0961,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786411800000},"marketStatusCode":5,"adr":0,"adjPreClose":9.29,"symbolType":"stock_kcb","openAndCloseTimeList":[[1786325400000,1786332600000],[1786338000000,1786345200000]],"highLimit":10.22,"lowLimit":8.36,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":453340000,"isCdr":false,"pbRate":3.23,"roa":"--","peRate":96.98231,"roe":"1.27%","epsLYR":0.11,"committee":-0.171243,"marketValue":4225000000,"turnoverRate":0.0223,"status":0,"afterMarket":{"amount":4660,"volume":500,"close":9.32,"buyVolume":800,"sellVolume":0,"time":1786347237746,"indexStatus":"已收盘 08-10 15:30:00","preClose":9.29},"floatMarketCap":4225000000},"requestUrl":"/m/hq/s/688247","defaultTab":"news","newsList":[{"id":"2657593579","title":"宣泰医药新提交“宣泰小红片”、“O'red”等3件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2657593579","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657593579?lang=zh_cn&edition=full","pubTime":"2026-08-05 07:30","pubTimestamp":1785886250,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示，近日上海宣泰医药科技股份有限公司新提交“宣泰小红片”、“O'red”等3件商标注册申请。商标申请详情如下：今年以来上海宣泰医药科技股份有限公司新申请注册商标3件，截止目前公司共持有注册商标166件，另有21件商标尚在注册申请中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500007697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657756567","title":"股市必读：宣泰医药新发布《自愿披露关于参与全国药品集中采购拟中选的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657756567","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657756567?lang=zh_cn&edition=full","pubTime":"2026-08-05 02:39","pubTimestamp":1785868751,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘，宣泰医药报收于8.6元，上涨8.59%，换手率2.85%，成交量12.91万手，成交额1.07亿元。公司公告汇总自愿披露关于参与全国药品集中采购拟中选的公告上海宣泰医药科技股份有限公司参与第十二批全国药品集中采购，其产品注射用硫酸艾沙康唑和合作开发产品恩扎卢胺片拟中选，采购周期至2029年12月31日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500002260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656937424","title":"宣泰医药(688247.SH)：注射用硫酸艾沙康唑等拟中选全国药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2656937424","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656937424?lang=zh_cn&edition=full","pubTime":"2026-08-03 21:38","pubTimestamp":1785764323,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药 发布公告，近日，公司参与了国家组织药品联合采购办公室组织的第十二批全国药品集中采购的投标，根据联采办于2026年7月31日在上海阳光医药采购网发布的《第12批国家组织药品集中带量采购拟中选结果公示》显示，公司产品注射用硫酸艾沙康唑、合作开发产品恩扎卢胺片拟中选本次集中采购。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654905773","title":"每周股票复盘：宣泰医药（688247）复杂注射剂产线试生产成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2654905773","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654905773?lang=zh_cn&edition=full","pubTime":"2026-07-26 03:05","pubTimestamp":1785006313,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，宣泰医药报收于8.17元，较上周的8.91元下跌8.31%。本周，宣泰医药7月20日盘中最高价报9.11元。本周关注点来自机构调研要点：复杂制剂车间预充针生产线已具备正常运行能力，并成功开展试生产。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600001013.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653086536","title":"宣泰医药：泊沙康唑肠溶片通过欧盟DCP核准","url":"https://stock-news.laohu8.com/highlight/detail?id=2653086536","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653086536?lang=zh_cn&edition=full","pubTime":"2026-07-24 18:37","pubTimestamp":1784889478,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652579230","title":"每周股票复盘：宣泰医药（688247）多索茶碱片通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2652579230","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652579230?lang=zh_cn&edition=full","pubTime":"2026-07-19 02:30","pubTimestamp":1784399430,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，宣泰医药报收于8.91元，较上周的8.91元上涨0.0%。本周，宣泰医药7月15日盘中最高价报9.67元。本周关注点公司公告汇总：多索茶碱片0.2g规格通过仿制药一致性评价，0.4g规格获批新增并同步通过评价。多索茶碱片适用于支气管哮喘、喘息性慢性支气管炎等引起的呼吸困难。该药品用于控制接受透析治疗的慢性肾脏病成人患者的高磷血症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651117702","title":"宣泰医药（688247）披露多索茶碱片通过仿制药一致性评价并新增规格公告，7月13日股价上涨2.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651117702","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651117702?lang=zh_cn&edition=full","pubTime":"2026-07-13 22:27","pubTimestamp":1783952833,"startTime":"0","endTime":"0","summary":"截至2026年7月13日收盘，宣泰医药报收于9.1元，较前一交易日上涨2.13%，最新总市值为41.25亿元。该股当日开盘8.91元，最高9.1元，最低8.75元，成交额达7738.58万元，换手率为1.91%。近日，宣泰医药披露《自愿披露关于多索茶碱片通过仿制药一致性评价并新增规格的公告》。公告显示，江苏宣泰药业有限公司收到国家药品监督管理局签发的多索茶碱片《药品补充申请批准通知书》，0.2g规格通过仿制药质量和疗效一致性评价，0.4g规格获批新增并同时通过一致性评价。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300040294.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649239694","title":"每周股票复盘：宣泰医药（688247）股价涨幅偏离值累计超30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649239694","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649239694?lang=zh_cn&edition=full","pubTime":"2026-07-05 02:39","pubTimestamp":1783190350,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，宣泰医药报收于9.41元，较上周的7.26元上涨29.61%。宣泰医药当前最新总市值42.66亿元，在化学制药板块市值排名106/149，在两市A股市值排名3592/5203。本周关注点来自交易信息汇总：宣泰医药因3日涨幅偏离值累计达30%两度登上龙虎榜。公司公告汇总股票交易异常波动公告上海宣泰医药科技股份有限公司股票于2026年7月1日和7月2日连续两个交易日内日收盘价格涨幅偏离值累计超过30%，构成股票交易异常波动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500000758.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648685476","title":"宣泰医药（688247）披露股票交易异常波动公告，7月2日股价上涨5.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648685476","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648685476?lang=zh_cn&edition=full","pubTime":"2026-07-02 22:28","pubTimestamp":1783002498,"startTime":"0","endTime":"0","summary":"截至2026年7月2日收盘，宣泰医药报收于9.52元，较前一交易日上涨5.54%，最新总市值为43.16亿元。近日，宣泰医药发布股票交易异常波动公告。公告显示，公司股票于2026年7月1日和7月2日连续两个交易日内日收盘价格涨幅偏离值累计超过30%，构成股票交易异常波动。公司董事会确认，除已披露事项外，无其他应披露未披露事项，亦未获悉可能对公司股票交易价格产生较大影响的信息。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200042152.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648591809","title":"异动快报：宣泰医药（688247）7月1日10点44分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2648591809","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648591809?lang=zh_cn&edition=full","pubTime":"2026-07-01 10:45","pubTimestamp":1782873926,"startTime":"0","endTime":"0","summary":"证券之星7月1日盘中消息，10点44分宣泰医药（688247）触及涨停板。其所属行业化学制药目前上涨。领涨股为宣泰医药。该股为上海国企改革，国企改革，创新药概念热股，当日上海国企改革概念上涨2.09%，国企改革概念上涨1.63%，创新药概念上涨1.39%。6月30日的资金流向数据方面，主力资金净流出156.61万元，占总成交额9.1%，游资资金净流入120.69万元，占总成交额7.01%，散户资金净流入35.91万元，占总成交额2.09%。近5日资金流向一览见下表：宣泰医药主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100016750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646316570","title":"每周股票复盘：XD宣泰医（688247）宣泰医药实施2025年度分红","url":"https://stock-news.laohu8.com/highlight/detail?id=2646316570","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646316570?lang=zh_cn&edition=full","pubTime":"2026-06-28 04:18","pubTimestamp":1782591493,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，XD宣泰医报收于7.26元，较上周的7.58元下跌4.22%。本周，XD宣泰医6月23日盘中最高价报7.95元。本周关注点公司公告汇总：宣泰医药2025年年度权益分派实施，每10股派0.10元（含税）。上海市锦天城律师事务所就上海宣泰医药科技股份有限公司2025年度利润分配涉及的差异化分红事项出具法律意见书。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800001444.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645002306","title":"宣泰医药（688247）披露2025年年度权益分派实施公告，6月22日股价下跌1.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645002306","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645002306?lang=zh_cn&edition=full","pubTime":"2026-06-22 17:49","pubTimestamp":1782121795,"startTime":"0","endTime":"0","summary":"截至2026年6月22日收盘，宣泰医药报收于7.5元，较前一交易日下跌1.06%，最新总市值为34亿元。该股当日开盘7.52元，最高7.54元，最低7.19元，成交额达2580.6万元，换手率为0.78%。公司于近日披露《2025年年度权益分派实施公告》。公告显示，本次利润分配经2026年5月28日年度股东会审议通过，以扣除回购专用证券账户股份后的总股本为基数，向全体股东每10股派发现金红利0.10元（含税），每股派发现金红利0.01元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200027030.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643721775","title":"每周股票复盘：宣泰医药（688247）股东减持279.24万股致股价跌15.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643721775","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643721775?lang=zh_cn&edition=full","pubTime":"2026-06-14 01:52","pubTimestamp":1781373136,"startTime":"0","endTime":"0","summary":"截至2026年6月12日收盘，宣泰医药报收于7.95元，较上周的8.06元下跌1.36%。本周，宣泰医药6月8日盘中最高价报8.23元。6月11日盘中最低价报7.7元，股价触及近一年最低点。宣泰医药当前最新总市值36.04亿元，在化学制药板块市值排名112/150，在两市A股市值排名3972/5206。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061400000460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642542818","title":"6月10日宣泰医药发布公告，股东减持279.24万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642542818","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642542818?lang=zh_cn&edition=full","pubTime":"2026-06-10 19:01","pubTimestamp":1781089296,"startTime":"0","endTime":"0","summary":"证券之星消息，6月10日宣泰医药发布公告《宣泰医药:关于持股5%以上股东减持计划时间届满暨减持股份结果公告》，其股东Finer Pharma Inc.于2026年4月15日至2026年6月10日间合计减持279.24万股，占公司目前总股本的0.616%，变动期间该股股价下跌15.66%，截止6月10日收盘报7.97元。股东增减持详情见下表：根据宣泰医药2026年一季报公布的十大股东详情如下：本文数据来源于宣泰医药公告，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000035584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641116464","title":"宣泰医药：公司于2026年5月11日参加了在上海证券交易所上证路演中心举办的“十五五·科创惠民——科创板企业成果转化与民生赋能之2025年度制药行业集体业绩说明会”","url":"https://stock-news.laohu8.com/highlight/detail?id=2641116464","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2641116464?lang=zh_cn&edition=full","pubTime":"2026-06-05 16:57","pubTimestamp":1780649874,"startTime":"0","endTime":"0","summary":"证券之星消息，宣泰医药06月05日在投资者关系平台上答复投资者关心的问题。公司于2026年5月11日参加了在上海证券交易所上证路演中心举办的“十五五·科创惠民——科创板企业成果转化与民生赋能之2025年度制药行业集体业绩说明会”，对公司2025年度及2026年一季度的经营情况做了详细解读，也对投资者关注的问题进行了回复，您可以通过上证路演中心官网查看本次说明会的详细内容。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500028794.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639028556","title":"每周股票复盘：宣泰医药（688247）盐酸安非他酮获哥伦比亚批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2639028556","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2639028556?lang=zh_cn&edition=full","pubTime":"2026-05-31 04:29","pubTimestamp":1780172949,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，宣泰医药报收于8.52元，较上周的8.91元下跌4.38%。本周关注点公司公告汇总：盐酸安非他酮缓释片获哥伦比亚INVIMA批准，具备当地市场销售资格。公司公告汇总自愿披露关于公司产品盐酸安非他酮缓释片获得哥伦比亚INVIMA批准文号的公告上海宣泰医药科技股份有限公司近日收到哥伦比亚国家药品和食品监督管理局通知，公司申报的盐酸安非他酮缓释片仿制药申请已获批准，具备在哥伦比亚市场销售的资格。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100001395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638694645","title":"宣泰医药（688247）披露2025年年度股东会决议公告，5月28日股价上涨1.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638694645","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638694645?lang=zh_cn&edition=full","pubTime":"2026-05-28 22:45","pubTimestamp":1779979512,"startTime":"0","endTime":"0","summary":"截至2026年5月28日收盘，宣泰医药报收于8.62元，较前一交易日上涨1.29%，最新总市值为39.08亿元。近日，上海宣泰医药科技股份有限公司发布《2025年年度股东会决议公告》。公告显示，公司于2026年5月28日召开2025年年度股东会，审议通过了2025年度利润分配方案、董事会工作报告、董事薪酬方案、聘任2026年度审计机构、未来三年股东分红回报规划等多项议案。出席会议股东所持表决权占公司总表决权的74.3988%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800043505.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638419533","title":"宣泰医药(688247.SH)：盐酸安非他酮缓释片获得哥伦比亚INVIMA批准文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2638419533","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638419533?lang=zh_cn&edition=full","pubTime":"2026-05-25 15:37","pubTimestamp":1779694672,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宣泰医药(688247.SH)发布公告，近日，公司收到哥伦比亚国家药品和食品监督管理局(简称“哥伦比亚INVIMA”)的通知，公司向其申报的盐酸安非他酮缓释片的仿制药申请获得正式批准。盐酸安非他酮缓释片的主要成分是盐酸安非他酮，盐酸安非他酮属于氨基酮类抗抑郁药，本次获批适应症为治疗重度抑郁症以及预防季节性情感障碍。本次盐酸安非他酮缓释片获得哥伦比亚INVIMA批准，标志着具备了在哥伦比亚市场销售该产品的资格，是公司在拉丁美洲市场取得的重要进展，将有利于公司未来不断扩大在拉丁美洲市场的销售规模，丰富产品梯队，对公司的长期经营产生积极的影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宣泰医药(688247.SH)：盐酸安非他酮缓释片获得哥伦比亚INVIMA批准文号","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637331376","title":"每周股票复盘：宣泰医药（688247）2025年净利降62.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637331376","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637331376?lang=zh_cn&edition=full","pubTime":"2026-05-24 04:32","pubTimestamp":1779568331,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，宣泰医药报收于8.91元，较上周的9.19元下跌3.05%。本周，宣泰医药5月20日盘中最高价报9.29元。截至2025年12月31日，募集资金尚有4,889.62万元未使用完毕，保荐机构将继续履行相关督导职责。2025年度，宣泰医药实现营业收入4.47亿元，同比下降12.71%；归属于母公司所有者的净利润为4748.28万元，同比下降62.82%。公司经营模式未发生重大变化，2025年度营业收入44,656.89万元，净利润4,748.28万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400001410.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637348315","title":"宣泰医药（688247）披露2025年年度股东会会议资料，5月22日股价下跌0.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637348315","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637348315?lang=zh_cn&edition=full","pubTime":"2026-05-22 22:37","pubTimestamp":1779460637,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，宣泰医药报收于8.91元，较前一交易日下跌0.45%，最新总市值为40.39亿元。该股当日开盘8.94元，最高9.03元，最低8.77元，成交额达2038.24万元，换手率为0.51%。近日，宣泰医药发布《2025年年度股东会会议资料》。公告显示，公司2025年年度股东会将审议九项议案，包括2025年度利润分配方案、董事会工作报告、2026年度董事薪酬方案、聘任2026年度审计机构、未来三年股东分红回报规划，以及董事会换届选举非独立董事与独立董事候选人等事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200045409.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688247"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1786382965693,"stockEarnings":[{"period":"1week","weight":0.1768},{"period":"1month","weight":0.046},{"period":"3month","weight":-0.0167},{"period":"6month","weight":-0.1035},{"period":"1year","weight":-0.2224},{"period":"ytd","weight":-0.0379}],"compareEarnings":[{"period":"1week","weight":0.0412},{"period":"1month","weight":-0.0074},{"period":"3month","weight":-0.0588},{"period":"6month","weight":-0.04},{"period":"1year","weight":0.0912},{"period":"ytd","weight":-0.0006}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海宣泰医药科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"7965人(较上一季度增加2.36%)","perCapita":"56916股","listingDate":"2022-08-25","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路780号7层709室","registeredCapital":"45334万元","survey":" 上海宣泰医药科技股份有限公司的主营业务是高端仿制药研发与产业化及创新药CRO/CMO一体化服务。公司的主要产品是美沙拉秦肠溶片、泊沙康唑肠溶片、熊去氧胆酸胶囊、盐酸安非他酮缓释片、碳酸司维拉姆片、西格列汀二甲双胍缓释片、达格列净二甲双胍缓释片。公司荣膺“2025中国医药CDMO企业20强”。","listedPrice":9.37},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宣泰医药(688247)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宣泰医药(688247)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宣泰医药,688247,宣泰医药股票,宣泰医药股票老虎,宣泰医药股票老虎国际,宣泰医药行情,宣泰医药股票行情,宣泰医药股价,宣泰医药股市,宣泰医药股票价格,宣泰医药股票交易,宣泰医药股票购买,宣泰医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宣泰医药(688247)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宣泰医药(688247)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}